{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:24:18Z","timestamp":1780579458738,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T00:00:00Z","timestamp":1687046400000},"content-version":"am","delay-in-days":290,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.05.024","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T23:36:34Z","timestamp":1655508994000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8878-4916","authenticated-orcid":false,"given":"Lambros","family":"Tselikas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Dardenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"de Baere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2331-0792","authenticated-orcid":false,"given":"Matthieu","family":"Faron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Ammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham","family":"Farhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Suzzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Danlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4574-3978","authenticated-orcid":false,"given":"Thibault","family":"Raoult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Susini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nael","family":"Al Shatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Mouraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4885-4366","authenticated-orcid":false,"given":"Alexandre","family":"Delpla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9584-3048","authenticated-orcid":false,"given":"Charles","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Champiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.05.024_bib1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2022.05.024_bib2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2022.05.024_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite\u00a0instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.024_bib4","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.05.024_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/357011a0","article-title":"Coley's toxins in perspective","volume":"357","author":"Starnes","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2022.05.024_bib6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/postgradmedj\/79.938.672","article-title":"Dr William Coley and tumour regression: a place in history or in the future","volume":"79","author":"Hoption Cann","year":"2003","journal-title":"Postgrad Med"},{"key":"10.1016\/j.ejca.2022.05.024_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: first in class oncolytic virotherapy","volume":"14","author":"Conry","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.ejca.2022.05.024_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001701","article-title":"Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany","volume":"9","author":"Ressler","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.05.024_bib9","doi-asserted-by":"crossref","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.05.024_bib10","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1158\/1078-0432.CCR-19-3642","article-title":"Intratumoral immunotherapy for early-stage solid tumors","volume":"26","author":"Hong","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.05.024_bib11","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/annonc\/mdy423","article-title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","volume":"29","author":"Marabelle","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.05.024_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001621","article-title":"Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma","volume":"9","author":"Malvehy","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2022.05.024_bib13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.024_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4049\/jimmunol.1601145","article-title":"Intratumoral delivery of immunotherapy-act locally, think globally","volume":"198","author":"Aznar","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2022.05.024_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.12.007","article-title":"Intratumoural immunotherapies in oncology","volume":"127","author":"Xu","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.05.024_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0391","article-title":"Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors","volume":"12","author":"Marquez-Rodas","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2022.05.024_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.05.024_bib18","doi-asserted-by":"crossref","first-page":"e2134","DOI":"10.1038\/cddis.2016.47","article-title":"The oncolytic peptide LTX-315 triggers immunogenic cell death","volume":"7","author":"Zhou","year":"2016","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ejca.2022.05.024_bib19","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.19.02985","article-title":"Response criteria for intratumoral immunotherapy in solid tumors: itRECIST","volume":"38","author":"Goldmacher","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.024_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for\u00a0melanoma immunotherapy","volume":"5","author":"Pol","year":"2016","journal-title":"OncoImmunology"},{"issue":"10","key":"10.1016\/j.ejca.2022.05.024_bib21","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/1078-0432.CCR-19-4073","article-title":"Interventional radiology for local immunotherapy in oncology","volume":"27","author":"Tselikas","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.05.024_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.7911","article-title":"Assessment of image-guided intratumoral delivery of immunotherapeutics in patients with cancer","volume":"3","author":"Sheth","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2022.05.024_bib23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/1078-0432.CCR-20-0473","article-title":"Intratumoral immunotherapy: from trial design to clinical practice","volume":"27","author":"Champiat","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.05.024_bib24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up\u00a0in\u00a0studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Contr Clin Trials"},{"key":"10.1016\/j.ejca.2022.05.024_bib25","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/1078-0432.CCR-19-4073","article-title":"Interventional radiology for local immunotherapy in oncology","volume":"27","author":"Tselikas","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.05.024_bib26","series-title":"WHO analgesic ladder","author":"Anekar","year":"2022"},{"key":"10.1016\/j.ejca.2022.05.024_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001800","article-title":"Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy","volume":"9","author":"Munoz","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:36:13Z","timestamp":1760733373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922003033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":27,"alternative-id":["S0959804922003033"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.05.024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}